Hedegaard had warned that the company might fire hundreds of workers and shut down a factory in Denmark if the Department of Health and Human Services didn’t order the work.
Bavarian Nordic’s Imvamune vaccine is meant for people with atopic dermatitis and compromised immune systems.
They are at risk of severe adverse reactions to the regular smallpox vaccine.
The new industry research award will ensure the U.S. has a total of 20 million doses of Bavarian Nordic’s smallpox vaccine in stock in case of a public health emergency.
Bavarian Nordic is guaranteed to receive $110 million for 4 million doses of its Imvamune vaccine.
The remaining $118 million, for another 4 million doses, hinges on the availability of U.S. funding next year, company officials said during the call.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View:Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View:Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View:Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity